Liver disease can result from injury to the liver caused by a variety of insults, including metabolic disease, chronic excessive alcohol use, autoimmune diseases, or viral hepatitis. Regardless of the underlying cause of the disease, there are important similarities in the disease progression including presence of NKT cells and increased inflammatory activity, which if unresolved leads to fibrosis. Fibrosis, if allowed to progress, will lead to cirrhosis, or excessive scarring of the liver, which often result in reduced liver function and the need for a liver transplant. We believe our novel approach, targeting NKT cells, will be a more effective approach then existing drug candidates targeting liver disease because we can interrupt the progression of the disease earlier in the inflammatory chain as well as multiple points during the course of disease progression.